#Denmark #Copenhagen #Hemab Therapeutics #HMB-002 #Von Willebrand Disease

Hemab Therapeutics Announces Velora Pioneer Clinical Trial

Hemab Therapeutics, a biotech company focused on innovative therapies for serious bleeding disorders, has taken a significant step forward by launching the Velora Pioneer clinical trial. This study investigates HMB-002, a groundbreaking subcutaneous therapy intended to treat Von Willebrand Disease (VWD), which has long been an under-addressed condition.

The Velora Pioneer trial began with the dosing of the first participant suffering from VWD, marking a pivotal moment for Hemab. Dr. Catherine Rea, the Vice President of Clinical Development at Hemab, expressed enthusiasm about HMB-002, stating that this treatment represents a fresh approach to managing VWD, which affects countless individuals living with this chronic bleeding disorder.

Understanding Von Willebrand Disease (VWD)

Von Willebrand Disease is the most prevalent inherited bleeding disorder, characterized by a deficiency or defect in von Willebrand factor (VWF) — a vital component for blood clotting. Individuals with VWD often experience excessive bleeding, which can lead to serious complications, including chronic iron deficiency anemia. Current treatments primarily focus on managing symptoms rather than resolving the underlying causes related to VWF dysfunction.

HMB-002 stands apart from existing therapies as it is specifically designed to increase endogenous levels of VWF and Factor VIII, crucial for effective hemostasis. By stabilizing VWF and promoting long-acting correction of bleeding tendencies among patients, HMB-002 has the potential to transform the lives of those affected by VWD.

The Science Behind HMB-002

The uniqueness of HMB-002 lies in its monovalent antibody design. This therapy is engineered to administer a fixed dose subcutaneously, making it more accessible for patients who require regular treatment. Preclinical studies have shown promising results, indicating that HMB-002 can enhance VWF and FVIII levels, which are typically deficient in VWD patients. Presentations at prominent healthcare congresses, such as the European Association for Haemophilia and Allied Disorders, have highlighted the encouraging preclinical data, underscoring its potential as a first-in-class therapeutic option.

Dr. Priyanka Raheja, a key investigator involved in the trial, remarked on the urgent need for more effective treatment options for VWD, emphasizing that HMB-002 could potentially correct the disease in some individuals while significantly mitigating bleeding risks in others.

Study Goals and Future Directions

The Phase 1/2 trial aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the overall efficacy of HMB-002. The initial phase involves single ascending doses administered in a controlled environment, with the first dosing conducted at Richmond Pharmacology in London, overseen by Principal Investigator Dr. Ulrike Lorch. The trial is currently open for participant enrollment, with interim results expected to be available later this year.

Hemab Therapeutics has been vocal about its mission to modernize the treatment landscape for VWD. Benny Sorensen, CEO of Hemab, stated that although VWD has been recognized for over a century, treatment methods have remained outdated and inconvenient. He is optimistic that HMB-002 can become a cornerstone therapy, transforming the way this condition is treated.

Moreover, Hemab is not solely focused on the Velora Pioneer trial; they are also rolling out Velora Discover, an extensive natural history study that aims to gather valuable data covering various aspects such as bleeding incidents, treatment responses, and overall quality of life for VWD patients. These insights are vital for understanding the treatments' impacts and refining therapeutic strategies.

In partnership with Haemnet — a specialist research consultancy concentrating on bleeding disorders — Hemab is conducting VWD 360, representing the largest natural history study of its kind. This collaborative effort seeks to capture the lived experiences of individuals with VWD and potentially reshape treatment paradigms based on a comprehensive understanding of patient needs.

In summary, Hemab Therapeutics and its innovative HMB-002 therapy signify a hopeful horizon for those affected by Von Willebrand Disease. With its focus on directly addressing the underlying causes and enhancing patients' quality of life, this study may lead the way to more efficient and effective treatment options in the years to come.